11 citations
,
April 2017 in “The European Journal of Contraception & Reproductive Health Care” Cyproterone acetate with ethinyl estradiol is effective for treating skin symptoms related to high androgen levels, like in PCOS.
September 2024 in “Annals of Medicine and Surgery” Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
14 citations
,
January 1980 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Both treatments reduced androgen levels and hair growth in women with hirsutism.
January 2021 in “Anais do Congresso Brasileiro de Reumatologia 2020” Tofacitinib improved arthritis and partially improved hair loss in a lupus patient without side effects.
December 2006 in “The Brown University Psychopharmacology Update” Second-generation antipsychotics offer no significant benefit over first-generation ones for schizophrenia.
1 citations
,
October 2025 in “Cureus” Ritlecitinib may cause severe musculoskeletal pain in some alopecia universalis patients.
6 citations
,
January 2023 in “Medical Mycology Journal” Fosravuconazole effectively treated a woman's scalp infection without side effects.
1 citations
,
March 1997 in “Journal of Chromatography B: Biomedical Sciences and Applications” Researchers developed a method to measure different forms of a drug that could help treat prostate issues and hair loss, and found how these forms behave in animals.
6 citations
,
April 2014 in “European journal of medicinal chemistry” New compounds similar to cromakalim were less effective at inhibiting insulin release but improved in solubility and one acted as a calcium entry blocker, not a potassium channel opener.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” The combination therapy is safe and more effective for treating pediatric facial and cervical vitiligo.
36 citations
,
July 2005 in “Journal of Neuroendocrinology” Blocking certain brain processes reduces mating behavior in female rats.
October 2023 in “IP Indian Journal of Clinical and Experimental Dermatology” The luliconazole shampoo effectively reduces symptoms of seborrheic dermatitis and is well-tolerated.
17 citations
,
October 2006 in “Molecular and Cellular Endocrinology” The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.
74 citations
,
December 1995 in “The Journal of Clinical Endocrinology & Metabolism” Leuprolide plus estrogen is more effective than oral contraceptives for reducing hirsutism.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
February 2026 in “Clinical and Experimental Dermatology” Bicalutamide improved hair growth more than spironolactone in women with hair loss.
21 citations
,
March 2021 in “Molecules” The new formulation greatly improved quercetin absorption in rats.
December 2012 in “http://isrctn.org/>”
December 2005 in “Endocrine-related cancer” A woman's adrenal tumor disappeared after treatment with cyproterone acetate.
88 citations
,
September 2003 in “Clinical endocrinology” Hormone treatment for transsexual individuals is effective but carries risks like thromboembolic events and mood changes, with most side effects being minor and reversible.
January 2026 in “Nature Reviews Urology” 12 citations
,
January 2018 in “Breast Cancer Basic and Clinical Research” Subcutaneous trastuzumab improves some symptoms and doesn't harm overall quality of life in breast cancer patients.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
The patch effectively promotes hair growth for alopecia areata without pain.
March 2022 in “Oncology Times” Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.
August 2002 in “Inpharma Weekly”
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.